

Express Mail No. EV 641 736 666 US

INFORMATION DISCLOSURE STATEMENT Address to: Mail Stop Box PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	RICE-050
	First Named Inventor	MACKAY, CHARLES REAY
	Application Number	10/584,480
	Confirmation No.	3065
	Filing Date	Not yet assigned
	Group Art Unit	Not yet assigned
	Examiner Name	Not yet assigned
Title: "TRANSGENIC NON-HUMAN MAMMAL COMPRISING A POLYNUCLEOTIDE ENCODING HUMAN OR HUMANIZED C5AR"		

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. RICE-050 may be charged thereon.


Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date:

April 17, 2007

By:



 Carol L. Francis, Ph.D.
 Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
 1900 University Avenue, Suite 200
 East Palo Alto, California 94303
 Telephone: (650) 327-3400
 Facsimile: (650) 327-3231

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	10/584,480
Filing Date	Not yet assigned
First Named Inventor	MACKAY, CHARLES REAY
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	RICE-050

[illegible]

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^o
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
/M.W./		WO 98/24893	06/11/1998	Abgenix, Inc.		
/M.W./		WO 94/20142	09/15/1994	Center for Blood Research, Inc.		
/M.W./		WO 95/00164	01/05/1995	The Scripps Research Institute		

Date Considered	09/18/2008
-----------------	------------

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/584,480	
			Filing Date	Not yet assigned	
			First Named Inventor	MACKAY, CHARLES REAY	
			Art Unit	Not yet assigned	
			Examiner Name	Not yet assigned	
Sheet	2	of	2	Attorney Docket Number	RICE-050

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/M.W./		Gerard, N. P. et al. Human chemotaxis receptor genes cluster at 19q13.3-13.4. characterization of the human C5a receptor gene. Biochemistry (1993), 32: 1243-1250.	
/M.W./		Höpken, U.E. et al. The C5a chemoattractant receptor mediates mucosal defence to infection, Nature (1996), 383: 86-89.	
/M.W./		Heller et al. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. The Journal of Immunology (1999) 163: 985-994.	
/M.W./		Köhl, J. et al. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Molecular Immunology (2001) 38: 175-187.	

Examiner Signature	/Michael Wilson/ (09/18/2008)	Date Considered	09/18/2008
-----------------------	-------------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.